HeartSciences 7/24/2025 Earnings Report

HeartSciences EPS Results

• Actual EPS: -$1.88
• Consensus EPS: -$2.51
• Beat/Miss: Beat by +$0.63
• One Year Ago EPS: N/A

HeartSciences Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

HeartSciences Announcement Details

• Date: 7/24/2025
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

HeartSciences (NASDAQ:HSCS), Inc. (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows. The technology has received regulatory clearance in key markets including the United States and European Union, and the company continues to forge distribution partnerships and develop direct sales channels to broaden its reach among cardiology practices, hospitals and primary care providers. Concurrently, HeartSciences is advancing its research efforts to explore additional clinical applications and refine its diagnostic algorithms.

Headquartered in Bothell, Washington, HeartSciences maintains research and development operations in the United States and collaborates with academic and clinical institutions to validate and expand its platform. As a publicly traded company on the NASDAQ exchange, HeartSciences is led by an executive team and governed by a board of directors committed to driving innovation in non‐invasive cardiovascular diagnostics. Through ongoing product development and strategic partnerships, the company aims to enhance patient outcomes and support clinicians with robust, data‐driven diagnostic tools.